Efficacy and safety of losartan in childhood immunoglobulin A nephropathy: a prospective multicenter study

Article information

Child Kidney Dis. 2023;27(2):97-104

Publication date (electronic) : 2023 December 7

doi : https://doi.org/10.3339/ckd.23.006

Hyesun Hyun^1,*, Yo Han Ahn^2,*, Eujin Park³, Hyun Jin Choi², Kyoung Hee Han⁴, Jung Won Lee⁵, Su Young Kim⁶, Eun Mi Yang⁷, Jin Soon Suh⁸, Jae Il Shin⁹, Min Hyun Cho¹⁰, Ja Wook Koo¹¹, Kee Hyuck Kim¹², Hye Won Park¹³, Il Soo Ha², Hae Il Cheong¹⁴, Hee Gyung Kang², Seong Heon Kim²

¹Department of Pediatrics, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea

³Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital, Seoul, Republic of Korea

⁴Department of Pediatrics, Jeju National University College of Medicine, Jeju, Republic of Korea

⁵Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Republic of Korea

⁶Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, Republic of Korea

⁷Department of Pediatrics, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea

⁸Department of Pediatrics, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

⁹Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea

¹⁰Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Republic of Korea

¹¹Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea

¹²Department of Pediatrics, NHIC Ilsan Hospital, Goyang, Republic of Korea

¹³Department of Pediatrics, Seoul National University Bundang Hospital, Sungnam, Republic of Korea

¹⁴Department of Pediatrics, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea

Correspondence to Seong Heon Kim Department of Pediatrics, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea E-mail: kimsh22@snu.ac.kr

*Hyesun Hyun and Yo Han Ahn contributed equally to this study as co-first authors.

Received 2023 March 9; Revised 2023 October 5; Accepted 2023 October 6.

Abstract

Introduction

Immunoglobulin A (IgA) nephropathy is the most common glomerular disease and is often diagnosed in children and young adults. Given that a considerable proportion of IgA nephropathy progresses to chronic kidney disease (CKD), especially when proteinuria is ≥1 g/day, the therapeutic goal is to reduce proteinuria. Blockage of the renin-angiotensin system (RAS) to reduce proteinuria has been the mainstay of IgA nephropathy treatment [1-4], along with various immunosuppressive medications [5-7].

The RAS is a hormonal system that plays a crucial role in blood volume and systemic vascular resistance. Activation of RAS results in increased blood pressure and sodium and water retention, subsequently increasing the effective circulating volume. RAS blockade reduces systemic and intraglomerular hydrostatic pressures by inhibiting angiotensin II-mediated efferent arteriolar vasoconstriction. Renal angiotensin II plays a major role in the development of renal fibrosis that progresses to end-stage renal failure, and the degree of proteinuria is known to be a risk factor for progression to kidney failure [8-10]. The ability of angiotensin II receptor blockers (ARBs) to reduce proteinuria, thereby delaying CKD progression, has been well-examined in diabetic nephropathy with proteinuria [11], leading to the approval of losartan and irbesartan for this indication. In IgA nephropathy, ARBs are frequently employed in combination with other therapeutic agents [12,13], and in adults, low-dose losartan was proven to reduce proteinuria [14]. Also, the blockade of RAS alone appears to be effective in children with proteinuria induced by kidney disease [15]. Among ARB, losartan has been approved by the U.S. Food and Drug Administration (FDA) for delaying CKD progression in proteinuric diabetic nephropathy along with irbesartan, although only losartan has been approved for children >5 years of age.

Angiotensin-converting enzyme inhibitors (ACEIs) are often selected as the first choice of RAS blocking agent; however, some patients fail to tolerate ACEIs and are switched to ARBs. A high incidence of ACEI-induced side effects such as dry cough has been documented in East Asia [16]. Therefore, ARBs have a relatively high clinical significance in this region. However, the use of ARBs for proteinuric glomerulopathy other than diabetic nephropathy remains off-label. In addition, the efficacy of ARB alone remains unexplored among pediatric patients with IgA nephropathy. In the present study, we performed a prospective multicenter study to confirm the efficacy and safety of losartan in reducing proteinuria in normotensive childhood IgA nephropathy with persistent proteinuria in Korea.

Methods

Results

Patients’ characteristics

In this prospective study, 29 subjects with biopsy-proven IgA nephropathy were enrolled and received losartan treatment at the median age of 12.2 years (IQR, 10.1–15.0 years). Among them, the UPCR was not assessed in one patient after receiving losartan, who was excluded from the FAS group (n=28). This group is defined as the intent-to-treat (ITT) population (Fig. 1). In the ITT group, three patients had hypertension before losartan administration, one patient exhibited a decreased eGFR <60 mL/min/1.73 m² at the 2-week visit after initiating losartan, and two did not complete the visit schedule; therefore, they were excluded from the PP group (n=22). Table 1 summarizes the basic clinical characteristics of the ITT group. The median disease duration was 3.12 years (IQR, 0.51–4.42 years). At enrollment, the median baseline proteinuria was 0.72 mg/mg (IQR, 0.48–0.95 mg/mg) in the FAS group.

Fig. 1.

Study disposition. ITT, intention to treat; PP, per-protocol.

Table 1.

Baseline characteristics of patients

Outcomes

In the ITT group, the mean log UPCR value before losartan administration was –0.34, which significantly decreased to –0.80 at 6 months of administration (P=0.003). In the PP group, we noted a significant decrease in the mean log UPCR value at 6 months of administration (P=0.02) (Fig. 2). In both groups, the mean log UPCR was significantly reduced 1 month after administration when compared with that before administration (Fig. 2). Following 6 months of treatment, proteinuria disappeared (UPCR was less than 0.2) in 14.3% (95% CI, 4.02%–32.7%) and 13.6% (95% CI, 2.90%–34.9%) of patients in the ITT and PP groups, respectively. Six months after treatment, a >50% reduction in UPCR was observed in 39.3% (95% CI, 21.2%–57.4%) and 36.7% (95% CI, 16.3%–56.5%) of the FAS and PP groups, respectively. The eGFR values before and after losartan administration did not differ significantly (Table 2).

Fig. 2.

Change of proteinuria. ITT, intention to treat; PP, per-protocol.

Table 2.

Changes in the estimated glomerular filtration rate

Safety

During the study period, nine (31.0%) of the 29 subjects who received losartan treatment experienced one or more adverse events. Overall, 26 adverse events were reported, of which one was a significant adverse reaction involving a cutaneous abscess that occurred in a 12-year-old male subject; however, there was no causal relationship with the drug (Table 3). No hyperkalemia or angioedema was observed during the study period. Following 6 months of losartan treatment, the median values for altered systolic and diastolic blood pressure were –2.50 mmHg (IQR, –5.50 to 9.00 mmHg) and –3.0 mmHg (IQR, –7.00 to 4.50 mmHg), respectively. There was a slight decrease in blood pressure, although symptoms such as dizziness were not observed (Table 4).

Table 3.

Reported adverse events and serious adverse events (n=26)

Table 4.

Changes in BP

Discussion

The ESCAPE (Effect of Strict Blood Pressure Control and ACE Inhibition on Progression of Chronic Renal Failure in Pediatric Patients) study and that by Webb et al. have confirmed the efficacy of RAS blockade for reducing proteinuria in children [17,18]. The ESCAPE study has revealed that strict blood pressure control can effectively delay the progression of CKD with proteinuria in children receiving ACEIs [18]. However, in the ESCAPE study, similar to several other studies conducted in adults, the efficacy of RAS inhibition for suppressing proteinuria was not examined independently from the effect of blood pressure reduction mediated by RAS inhibition on proteinuria. In addition, the underlying diseases of the study participants were heterogeneous. In the present study, the efficacy of RAS inhibition on proteinuria in pediatric IgA nephropathy was evaluated independently of the antihypertensive effect of losartan. According to the study by Webb et al. [17], losartan could effectively reduce proteinuria in pediatric patients with CKD when compared with a calcium channel blocker, amlodipine or placebo. Although amlodipine and placebo increased proteinuria by 1.4%, losartan reduced proteinuria by 35.8%. In addition, several prospective studies have evaluated the efficacy and safety of ACEIs with or without ARB in children [19-21]. A randomized controlled trial assessing pediatric patients with IgA nephropathy in Japan has supported lisinopril monotherapy in reducing proteinuria when compared with combination therapy with lisinopril and losartan. The cumulative disappearance rate of proteinuria at 24 months was 89.3% with combination therapy and 89% for monotherapy, without differences in safety [19]. Conversely, the long-term efficacy of losartan and enalapril treatment revealed that the reduction in proteinuria at 3 years was 30.0% for losartan and 40.5% for enalapril [20]. These studies have shown that either ACEI or ARB therapy can be effective in pediatric patients with IgA nephropathy.

In the present study, we aimed to evaluate the efficacy and safety of losartan in children with IgA nephropathy and provide medical evidence for the use of losartan in children with proteinuric kidney disease in Korea. Losartan is an angiotensin II type I receptor blocker that blocks the angiotensin system, inhibits kidney damage, and reduces urinary proteinuria. To the best of our knowledge, this is the first prospective clinical study to examine the potential of losartan monotherapy in children with IgA nephropathy. Our study supports the finding that losartan could effectively reduce proteinuria in pediatric patients with IgA nephropathy.

IgA nephropathy is known to exhibit a relatively benign clinical course in children when compared with that in adults [22-25]. In a Japanese study, although adult IgA nephropathy was found to progress to kidney failure in 10%–20% and 50% of patients within 10 and 20 years, respectively, kidney survival rates at 10- and 20-year were 95% and 82%, respectively, in children [23]. In a retrospective study assessing 99 pediatric patients with IgA nephropathy and 125 adult patients with IgA nephropathy, pediatric patients were more likely to display minimal histologic lesions, and 10-year kidney survival was 87% in children when compared with 48% in adults [26]. In children, the probability of spontaneous remission without treatment was found to be higher than the predicted probability [27]. Most subjects in this study also showed improvements in proteinuria with losartan treatment.

A recent study from Korea has shown that 65 (5.6%) of 1,154 pediatric patients with IgA nephropathy developed CKD stage 3-5 during a median follow-up of 5 years. In total, 947 patients were treated with RAS blockers with or without additional immunosuppressive drugs, and 207 patients (17.9%) received no pharmacologic treatments. Considering proteinuria, the authors found that 839 patients (72.7%) achieved remission. Moreover, remission was found to be an independent prognostic factor that negatively correlated with the progression of CKD stage 3-5 (hazard ratio, 0.19; 95% CI, 0.06–0.26; P<0.001) [28]. Accordingly, these findings highlight that the prognosis of children with IgA nephropathy in Korea is relatively good, and achieving remission indicates a favorable outcome of IgA nephropathy.

Few studies have established that losartan can be safely used in children and adolescents [18,29]. Dizziness or headache is common due to drug-related adverse reactions, which can be reversed by appropriate dose adjustment, and sometimes due to side effects, in which case the medication may be withdrawn for a short period and subsequently re-initiated [18]. Compared with ACEIs, losartan can be safely employed in terms of potential side effects [20,30]. However, when combined with tacrolimus, careful attention should be paid to hyperkalemia and metabolic acidosis. In addition, hyperkalemia may occur when losartan is combined with ACEI in CKD, and potassium concentration should be observed [21,31]. Herein, we observed no adverse events, such as decreased blood pressure, reduced GRF, or hyperkalemia, during the 24-week study period. There were no instances of relatively common side effects such as angioedema or hyperkalemia, which may be attributed to the limited number of subjects in the study. In the present study, losartan was initiated at a dose of 0.7 mg/kg/day, once daily, and was gradually increased (12.5–25.0 mg/day) up to a maximum dose of 1.5 mg/kg/day or 100 mg/day. For children, doses were initially estimated using adult doses, and the dose of losartan used in the present study is known to be safe for children and adolescents [17,19,20,32]. Considering children ˂6 years of age undergoing treatment for hypertension, doses of 0.1 to 0.7 mg/kg are effective, and doses of 1.4 mg/kg can be used without difficulty [32].

The present study was the first prospective, multicenter study conducted in Korea. However, its limitations need to be stated, including the relatively short study period, a small number of study subjects, and a single-arm design. An additional limitation of this study lies in the absence of consideration of histopathological findings for IgA nephropathy. The inclusion criteria encompassed children between 24 months and 18 years of age. However, since all enrolled participants were 6 years or older, the assessment of efficacy and safety in patients below this age threshold is limited

In conclusion, this study represents the first multicenter study for the use of losartan in pediatric patients with IgA nephropathy within our country. The results of this study demonstrate that losartan treatment led to a substantial reduction in proteinuria among children with IgA nephropathy, all while exhibiting a favorable safety profile devoid of severe adverse events. As such, these findings support the effective and safe application of losartan in managing IgA nephropathy in pediatric populations.

Article information Continued